Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    TETRA Technologies Inc.

    NYSE: TTI · Real-Time Price · USD
    3.49
    -0.10 (-2.79%)
    At close: Jun 13, 2025, 3:59 PM
    3.60
    3.15%
    After-hours: Jun 13, 2025, 05:58 PM EDT
    -2.79%
    Bid 3.48
    Market Cap 464.42M
    Revenue (ttm) 605.28M
    Net Income (ttm) 110.93M
    EPS (ttm) 0.88
    PE Ratio (ttm) 3.97
    Forward PE 10.2
    Analyst Buy
    Ask 3.61
    Volume 1,366,985
    Avg. Volume (20D) 1,536,469
    Open 3.68
    Previous Close 3.59
    Day's Range 3.47 - 3.70
    52-Week Range 2.03 - 5.12
    Beta 1.33

    About TTI

    undefined

    [Read more]
    Industry n/a
    Sector n/a
    IPO Date n/a
    Employees NaN
    Stock Exchange n/a
    Ticker Symbol TTI
    Website n/a
    Full Company Profile

    Analyst Forecast

    According to 0 analyst ratings, the average rating for TTI stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

    Stock Forecasts

    Why Price Moved

    Why Price Moved is a one-sentence explanation of why a stock is moving higher or down. By removing noise and collecting signals from news, press releases and SEC filings, we can pinpoint the trigger for price movements.
    2 days ago
    +18.93%
    Shares of energy stocks are trading higher amid a ... Unlock content with Pro Subscription
    1 month ago
    +3.26%
    TTI stock has given up its prior gain. Tetra Technologies shares were trading higher following a Q1 adjusted EPS beat.
    news image

    1 day ago · newsfilecorp.com

    Thiogenesis Announces Grant of Stock Options

    San Diego, California--(Newsfile Corp. - June 12, 2025) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) (OTCQX: TTIPF) ("Thiogenesis" or the "Company") a clinical-stage biotechnology company developing ...

    news image

    2 days ago · newsfilecorp.com

    Thiogenesis Announces FDA Clearance of its Investigational New Drug Application ("IND") for a Phase 2a Clinical Trial in Leigh Syndrome Spectrum

    San Diego, California--(Newsfile Corp. - June 11, 2025) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) (OTCQX: TTIPF) ('Thiogenesis' or the 'Company') a clinical-stage biotechnology company developing ...

    news image

    2 weeks ago · businesswire.com

    Tvardi Therapeutics Announces Completion of Enrollment in Phase 2 Clinical Trial of TTI-101 in Idiopathic Pulmonary Fibrosis

    HOUSTON--(BUSINESS WIRE)-- #IdiopathicPulmonaryFibrosis--Tvardi Therapeutics, Inc. (“Tvardi”) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, smal...

    news image

    1 month ago · newsfilecorp.com

    Thiogenesis Initiates Phase 2 Clinical Trial in Mitochondrial Encephalomyopathy with Lactic Acidosis and Stroke-like Episodes ("MELAS")

    San Diego, California--(Newsfile Corp. - May 14, 2025) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) (OTCQX: TTIPF) ("Thiogenesis" or the "Company") a clinical-stage biotechnology company developing d...

    news image

    1 month ago · newsfilecorp.com

    Tetra Technologies Announces Participation in the D. Boral Capital Inaugural Global Conference

    The Woodlands, Texas--(Newsfile Corp. - May 6, 2025) - Tetra Technologies (NYSE: TTI) today announced its participation in the D. Boral Capital Inaugural Global Conference, taking place May 14, 2025, ...

    news image

    1 month ago · seekingalpha.com

    TETRA Technologies, Inc. (TTI) Q1 2025 Earnings Call Transcript

    TETRA Technologies, Inc. (NYSE:TTI ) Q1 2025 Results Conference Call April 30, 2025 10:30 AM ET Company Participants Kurt Hallead - VP, Treasurer and Head of Investor Relations Brady Murphy - Presiden...

    news image

    1 month ago · zacks.com

    Tetra Technologies (TTI) Surpasses Q1 Earnings and Revenue Estimates

    Tetra Technologies (TTI) came out with quarterly earnings of $0.11 per share, beating the Zacks Consensus Estimate of $0.08 per share. This compares to earnings of $0.05 per share a year ago.

    news image

    1 month ago · zacks.com

    Tetra Technologies (TTI) Earnings Expected to Grow: Should You Buy?

    Tetra Technologies (TTI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

    Add to Watchlist